Ad is loading...
CYBN
Price
$11.60
Change
+$0.60 (+5.45%)
Updated
Nov 15 closing price
SNPX
Price
$2.40
Change
-$0.21 (-8.05%)
Updated
Nov 15 closing price
Ad is loading...

CYBN vs SNPX

Header iconCYBN vs SNPX Comparison
Open Charts CYBN vs SNPXBanner chart's image
Cybin
Price$11.60
Change+$0.60 (+5.45%)
Volume$2.16M
CapitalizationN/A
Synaptogenix
Price$2.40
Change-$0.21 (-8.05%)
Volume$22.49K
CapitalizationN/A
CYBN vs SNPX Comparison Chart
Loading...
CYBN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SNPX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
CYBN vs. SNPX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYBN is a StrongSell and SNPX is a Sell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (CYBN: $11.60 vs. SNPX: $2.40)
Brand notoriety: CYBN and SNPX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYBN: 781% vs. SNPX: 85%
Market capitalization -- CYBN: $220.31M vs. SNPX: $3.25M
CYBN [@Biotechnology] is valued at $220.31M. SNPX’s [@Biotechnology] market capitalization is $3.25M. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYBN’s FA Score shows that 1 FA rating(s) are green whileSNPX’s FA Score has 1 green FA rating(s).

  • CYBN’s FA Score: 1 green, 4 red.
  • SNPX’s FA Score: 1 green, 4 red.
According to our system of comparison, CYBN is a better buy in the long-term than SNPX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYBN’s TA Score shows that 6 TA indicator(s) are bullish while SNPX’s TA Score has 4 bullish TA indicator(s).

  • CYBN’s TA Score: 6 bullish, 4 bearish.
  • SNPX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CYBN is a better buy in the short-term than SNPX.

Price Growth

CYBN (@Biotechnology) experienced а +7.61% price change this week, while SNPX (@Biotechnology) price change was -18.64% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

CYBN is expected to report earnings on Nov 13, 2024.

SNPX is expected to report earnings on May 29, 2024.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYBN($220M) has a higher market cap than SNPX($3.25M). CYBN YTD gains are higher at: -25.546 vs. SNPX (-64.693). SNPX has higher annual earnings (EBITDA): -6.83M vs. CYBN (-85.95M). CYBN (0) and SNPX (0) have equivalent revenues.
CYBNSNPXCYBN / SNPX
Capitalization220M3.25M6,763%
EBITDA-85.95M-6.83M1,259%
Gain YTD-25.546-64.69339%
P/E RatioN/A0.23-
Revenue00-
Total CashN/A27.4M-
Total DebtN/AN/A-
TECHNICAL ANALYSIS
Technical Analysis
CYBNSNPX
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
85%
Momentum
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 3 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
59%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
57%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 11 days ago
82%
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
78%
N/A
View a ticker or compare two or three
Ad is loading...
CYBN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SNPX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MSAAX16.210.01
+0.06%
Morgan Stanley Inst Passport ovrs eq C
OIEMX9.77N/A
N/A
Oberweis Emerging Markets Institutional
FASDX17.66-0.05
-0.28%
Fidelity Advisor Strategic Div & Inc A
HFETX45.19-0.59
-1.29%
Janus Henderson European Focus T
PXLIX15.13-0.22
-1.43%
Impax Large Cap Fund Institutional

CYBN and

Correlation & Price change

A.I.dvisor indicates that over the last year, CYBN has been loosely correlated with ATAI. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if CYBN jumps, then ATAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYBN
1D Price
Change %
CYBN100%
+5.45%
ATAI - CYBN
34%
Loosely correlated
+17.52%
SNPX - CYBN
30%
Poorly correlated
-8.05%
MNMD - CYBN
30%
Poorly correlated
-7.51%
HEPA - CYBN
29%
Poorly correlated
+2.26%
CING - CYBN
25%
Poorly correlated
-0.47%
More

SNPX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SNPX has been closely correlated with NCNA. These tickers have moved in lockstep 92% of the time. This A.I.-generated data suggests there is a high statistical probability that if SNPX jumps, then NCNA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SNPX
1D Price
Change %
SNPX100%
-8.05%
NCNA - SNPX
92%
Closely correlated
-3.87%
RNAC - SNPX
91%
Closely correlated
+1.82%
AGEN - SNPX
91%
Closely correlated
-1.81%
ALLR - SNPX
87%
Closely correlated
-6.38%
NRXP - SNPX
84%
Closely correlated
+2.59%
More